ClinicalTrials.gg

Program

cadonilimab

Also written as “AK104”, “Cadonilimab” and “Cadonilimab (AK104)”.

Its studies are mostly in Carcinoma, Hepatocellular · Carcinoma, Non-Small-Cell Lung · Uterine Cervical Neoplasms · Carcinoma, Renal Cell · Stomach Neoplasms, led by 4 companies.

Furthest: phase 3, since Jul 21, 202145 company-led studies, 22 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Akeso4219 open or runningphase 3since Jul 21, 2021Aug 20, 2017Nov 2026phase 3 · NCT06341335
RemeGen11 open or runningphase 3since Jan 15, 2024Jan 15, 2024Dec 2026phase 3 · NCT06221748
Shanghai Pharmaceuticals11 open or runningphase 2since Jul 6, 2023Jul 6, 2023Dec 31, 2026phase 2 · NCT05944224
Summit Therapeutics11 open or runningphase 2since Sep 29, 2026Sep 29, 2026Apr 12, 2029phase 2 · NCT07877194

Also a collaborator on its studies: Chipscreen Biosciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 32 studies since Aug 20, 2017.

  1. Mar 26, 2024Phase 3 study in Gastric and Gastroesophageal Junction AdenocarcinomaAkeso · NCT06341335 · 506 planned · China
  2. Apr 15, 2024Phase 3 study in Carcinoma, HepatocellularAkeso · NCT06371157 · 469 planned · China
  3. Aug 15, 2024Phase 2 study in Ovarian NeoplasmsAkeso · NCT06560112 · 172 planned · China
  4. Sep 25, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungAkeso · NCT06617416 · 560 planned · China
  5. Oct 16, 2024Phase 2 study in Metastatic Pancreatic Ductal AdenocarcinomaAkeso · NCT06646055 · 110 enrolled · China
  6. May 15, 2025Phase 2 study in Carcinoma, HepatocellularAkeso · NCT06984718 · 120 planned
  7. Jun 10, 2025Phase 3 study in AdenocarcinomaAkeso · NCT07023315 · 760 planned · China
  8. Nov 24, 2025Phase 2 study in Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaAkeso · NCT07263919 · 90 planned · China
  9. Feb 9, 20262 phase 3 studiesAkeso · NCT07412613, NCT07449780
  10. May 26, 2026Phase 1 study in Healthy Male Adults ParticipantsAkeso · NCT07619001 · 158 planned · China
  11. Jul 8, 2026Phase 3 study in Stomach NeoplasmsAkeso · NCT07700979 · 900 planned · United States, China, Germany and more
  12. Sep 28, 2026Phase 2 study terminatedStudy stoppedNCT05932212 · “Sponsor decision”
  13. Sep 29, 2026Summit Therapeutics's first study: phase 2 study in Carcinoma, Renal CellNew to Summit TherapeuticsSummit Therapeutics · NCT07877194 · 100 planned · United States, China
  14. Nov 12, 2026Primary completion moved from 2026-11-05 to 2028-06-30Date moved laterphase 1 · +20 months · NCT06929663

Ahead

  1. Nov 2026Primary completion: phase 3 study in Gastric and Gastroesophageal Junction AdenocarcinomaAkeso · NCT06341335
  2. Nov 30, 2026Primary completion: phase 2 study in Carcinoma, HepatocellularAkeso · NCT06984718
  3. Dec 2026Primary completion: phase 3 study in Stomach NeoplasmsRemeGen · NCT06221748
  4. Dec 30, 2026Primary completion: phase 2 study in Metastatic Pancreatic Ductal AdenocarcinomaAkeso · NCT06646055

TargetBeta

CTLA4 →PDCD1 →read by rule
“A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), ”NCIt, by rule
“Programmed cell death protein 1 inhibitor; Cytotoxic T-lymphocyte protein 4 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
lorigerlimabruleMacroGenicsphase 24
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22

Studies

All 45 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07877194Carcinoma, Renal Cell · United States, China2Not yet recruitingSummit TherapeuticsApr 12, 2029100
NCT07700979Stomach Neoplasms · United States, China, Germany and more3RecruitingAkesoAug 18, 2029900
NCT07619001Healthy Male Adults Participants · China1Not yet recruitingAkesoSep 30, 2026158
NCT07449780Gastric / Gastroesophageal Junction Adenocarcinoma3Not yet recruitingAkesoNov 17, 2027422
NCT07412613Resectable Colon Cancer · China3RecruitingAkesoJun 15, 2030386
NCT07263919Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma · China2RecruitingAkesoMar 203090
NCT07023315Adenocarcinoma · China3RecruitingAkesoJul 2029760
NCT06984718Carcinoma, Hepatocellular2Not yet recruitingAkesoNov 30, 2026120
NCT06646055Metastatic Pancreatic Ductal Adenocarcinoma · China2Active, not recruitingAkesoDec 30, 2026110
NCT06617416Carcinoma, Non-Small-Cell Lung · China3RecruitingAkesoOct 28, 2026560
NCT06560112Ovarian Neoplasms · China2RecruitingAkesoMay 1, 2026172
NCT06371157Carcinoma, Hepatocellular · China3RecruitingAkesoOct 25, 2025469
NCT06341335Gastric and Gastroesophageal Junction Adenocarcinoma · China3RecruitingAkesoNov 2026506
NCT06221748Stomach Neoplasms · China3RecruitingRemeGenDec 202690
NCT05990127Carcinoma, Non-Small-Cell Lung · China3Not yet recruitingAkesoAug 5, 2025642
NCT05944224Advanced Solid Tumors · China2RecruitingShanghai PharmaceuticalsDec 31, 202663
NCT05932212Vulvar Neoplasms · China2TerminatedAkesoMay 31, 202620
NCT05904379Advanced Non-small-cell Lung Cancer · China2Active, not recruitingAkesoJun 30, 2026233
NCT05559554Healthy Male Subjects · China1CompletedAkesoMar 24, 2023100
NCT05559541Solid Tumor, Adult · China2TerminatedAkesoMay 31, 202433
NCT05505825SCLC,Extensive Stage · Australia, China2CompletedAkesoJul 19, 202436
NCT05489289Carcinoma, Hepatocellular · China3RecruitingAkesoJan 28, 2026570
NCT05319431Unresectable, Non-metastatic Hepatocellular Carcinoma · China2Active, not recruitingAkesoAug 15, 202360
NCT05227651Uterine Cervical Neoplasms · China2CompletedAkesoSep 27, 202414
NCT05235542Advanced Malignant Tumors · China2CompletedAkesoMay 9, 2026128
NCT05256472Carcinoma, Renal Cell · China2CompletedAkesoDec 31, 202528
NCT05235516Locally Advanced Cervical Carcinoma · China3Active, not recruitingAkesoMay 2026636
NCT05215067Advanced Non-small Cell Lung Cancer · China2CompletedAkesoJan 30, 202644
NCT05142423Advanced Solid Tumor · China2RecruitingAkesoApr 2027198
NCT05021120Advanced or Metastatic Solid Tumours · AustraliaEarly 1CompletedAkesoOct 1, 202467
NCT05008783Gastric Adenocarcinoma · China3CompletedAkesoDec 6, 2024610
NCT04982237Uterine Cervical Neoplasms · China3Active, not recruitingAkesoDec 30, 2025445
NCT04868708Recurrence · China2CompletedAkesoFeb 28, 202450
NCT04728321Carcinoma, Hepatocellular · China2CompletedAkesoAug 2, 202232
NCT04646330NSCLC · China2CompletedAkesoOct 26, 2023114
NCT04647344Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV · China2CompletedAkesoDec 31, 202346
NCT04572152Advanced or Metastatic Solid Tumors · Australia1CompletedAkesoMay 2, 202323
NCT04547101MSI-H/dMMR Solid Tumor · China2TerminatedAkesoSep 30, 20226
NCT04444167Carcinoma, Hepatocellular · China2CompletedAkesoNov 20, 202359
NCT04444141Lymphoma, T-Cell, Peripheral · China2TerminatedAkesoSep 30, 20226
NCT04380805Uterine Cervical Neoplasms · United States, Australia, New Zealand2CompletedAkesoDec 22, 202230
NCT04220307Nasopharyngeal Carcinoma · China2CompletedAkesoMay 15, 202134
NCT04172454Melanoma · China2CompletedAkesoJun 17, 202168
NCT03852251Diabetes Mellitus, Insulin-Dependent, 12 · China2CompletedAkesoMar 25, 2024338
NCT03261011Advanced Cancer · Australia1CompletedAkesoAug 27, 2021119

How it is read

Names in the registry

  • “AK104”, 26 entries
  • “Cadonilimab”, 3 entries
  • “Cadonilimab (AK104)”, 3 entries
  • “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”, 3 entries
  • “AK104+anlotinib”, 3 entries

Codes read as this program: AK104.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.